Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants With Post-Traumatic Stress Disorder (PTSD)

NCT05181995 is registered in ClinicalTrials.gov with Aptinyx as lead sponsor.

NCT NCT05181995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05181995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants With Post-Traumatic Stress Disorder (PTSD)
Lead sponsor
Aptinyx
Phase
Phase 2/3
Overall status
Terminated
Start date
December 13, 2021
Completion date
March 30, 2023
Enrollment
121 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd